1 November 2018
Albumin To prevent Infection in chronic liver failure
ATTIRE is a randomised controlled trial to investigate the use of albumin in patients with advanced liver cirrhosis. ATTIRE is funded by the Department of Health and Wellcome Trust.
Liver cirrhosis results in liver tissue becoming scarred and developing lumps. These changes can prevent the liver from functioning properly. There are about 60,000 patient admissions each year due to complications of liver cirrhosis. These patients are at a higher risk of developing an infection during their hospital stay due to a weakened immune system.
One function of the liver is to produce albumin. Patients with liver cirrhosis may have albumin levels in the blood much lower than normal. This trial is investigating whether boosting albumin levels through targeted infusions of 20% Human Albumin Solution will reverse immune suppression and prevent infection.
The primary outcome for ATTIRE is the incidence of infection during the hospital admission.
- China L, Muirhead N, Skene SS, Shabir Z, De Maeyer RPH, Maini AAN, Gilroy DW, O'Brien AJ. ATTIRE: Albumin To prevenT Infection in chronic liveR failurE: study protocol for a single-arm feasibility trial. BMJ Open 2016; 6: e010132
- China L, Skene SS, Shabir Z, Maini AA, Sylvestre Y, Bennett K, Bevan S, O'Beirne J, Forrest E, Portal J, Ryder S, Wright G, Gilroy DW, O'Brien A. Administration of Albumin Solution Increases Serum Levels of Albumin in Patients with Chronic Liver Failure in a Single-arm Feasibility Trial. Clinical Gastroenterology and Hepatology, Article in press; Published online: 11 Sep 2017
- China L, Maini AA, Skene SS, Shabir Z, Sylvestre Y, Colas RA, Ly L, Salles NB, Belloti V, Dalli J, Gilroy DW, O'Brien A. Albumin Counteracts Immune-suppressive effects of lipid mediators in patients with advanced liver disease Clinical Gastroenterology and Hepatology, 2017 Aug 28; Article in press; Published online: 30 Aug 2017